28 January 2026 - Dong-A ST announced on Wednesday that Health Canada has granted marketing authorisation for Imuldosa (ingredient: ustekinumab), a biosimilar to Janssen’s blockbuster drug Stelara.

Stelara, the reference product, is a major biologic treatment that recorded global sales of approximately $21.55 billion (28.75 trillion won) in 2024, according to IQVIA data.

Read Korea Biomedical Review article